Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERvE: Benzathine Penicillin to Prevent Maternal Syphilis
NCT07189208Phase 2Recruiting
- Sponsor
- University of California, Los Angeles
- Start
- Sep 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of benzathine penicillin G in syphilis and congenital syphilis (CS) (2 arms), sponsored by University of California, Los Angeles. Primary endpoint: Number of participants with absence of maternal syphilis infection. Started Sep 2025; status: recruiting.
02
Drugs
benzathine penicillin G
03
Conditions
syphiliscongenital syphilis (CS)
Beyond the preview
Go deeper on NCT07189208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07189208.